Last reviewed · How we verify
Tedizolid (BAY119-2631)
Tedizolid (BAY119-2631) is a oxazolidinone antibiotic Small molecule drug developed by Bayer. It is currently in Phase 3 development for Acute bacterial skin and skin structure infections (ABSSSI).
Tedizolid is an oxazolidinone antibiotic that inhibits protein synthesis in bacteria.
Tedizolid is an oxazolidinone antibiotic that inhibits protein synthesis in bacteria. Used for Acute bacterial skin and skin structure infections (ABSSSI).
At a glance
| Generic name | Tedizolid (BAY119-2631) |
|---|---|
| Sponsor | Bayer |
| Drug class | oxazolidinone antibiotic |
| Target | 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Tedizolid works by binding to the 50S ribosomal subunit of bacteria, preventing the formation of the 70S initiation complex and thereby inhibiting protein synthesis. This leads to the death of the bacterial cell. Tedizolid has a broad spectrum of activity against Gram-positive bacteria, including MRSA.
Approved indications
- Acute bacterial skin and skin structure infections (ABSSSI)
Common side effects
- Nausea
- Diarrhea
- Headache
- Vomiting
- Abdominal pain
Key clinical trials
- Sivextro in Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Hospitalized Patients. A Global Observational Study
- Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections (PHASE3)
- Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tedizolid (BAY119-2631) CI brief — competitive landscape report
- Tedizolid (BAY119-2631) updates RSS · CI watch RSS
- Bayer portfolio CI
Frequently asked questions about Tedizolid (BAY119-2631)
What is Tedizolid (BAY119-2631)?
How does Tedizolid (BAY119-2631) work?
What is Tedizolid (BAY119-2631) used for?
Who makes Tedizolid (BAY119-2631)?
What drug class is Tedizolid (BAY119-2631) in?
What development phase is Tedizolid (BAY119-2631) in?
What are the side effects of Tedizolid (BAY119-2631)?
What does Tedizolid (BAY119-2631) target?
Related
- Drug class: All oxazolidinone antibiotic drugs
- Target: All drugs targeting 50S ribosomal subunit
- Manufacturer: Bayer — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Acute bacterial skin and skin structure infections (ABSSSI)